Recall warning: Don't feed this popular mix to your pets due to salmonella, listeria fears
Pet owners across several states are on high alert following a recall of a popular kitten and puppy mix due to potential contamination with salmonella and listeria.
Blue Ridge Beef is recalling over 2,300 pounds of its 2-pound logs of Kitten Mix and Puppy Mix products that were distributed to retail locations throughout the eastern United States and Wisconsin, according to a statement from the Food and Drug Administration.
The products, identified by their clear plastic packaging, were shipped between January 3 and January 24. These states include Massachusetts, Virginia, Maryland, Pennsylvania, Connecticut, New York, Tennessee, Rhode Island and Wisconsin.
Salmonella and Listeria in pet food can impact the health of both animals eating the product and humans who handle it. The FDA emphasizes that individuals who have come in contact with the recalled food, especially if they have not rigorously washed their hands afterward, are at risk of infection.
Pets infected with Salmonella or Listeria may exhibit signs such as lethargy, diarrhea (potentially containing blood), fever, and vomiting. Some animals might also show a decrease in appetite, fever and abdominal pain.
The FDA cautions that infected pets who are otherwise healthy can become carriers of these bacteria, potentially spreading the infection to other animals and humans. Owners are advised to contact a veterinarian if their pet has consumed the Blue Ridge food mix.
The FDA also outlined potential health risks for humans exposed to the contaminated pet food. Healthy individuals should monitor themselves for common symptoms, including nausea, vomiting, diarrhea (which can be bloody), abdominal cramping and fever.
The agency noted that in rare instances, Salmonella and Listeria can lead to more serious conditions, including arterial infections, endocarditis (inflammation of the heart lining), arthritis, muscle pain, eye irritation and urinary tract symptoms. Individuals experiencing any of these more serious signs are advised to contact their healthcare provider, the FDA wrote.
Customers who have purchased the specific 2-pound logs of Kitten Mix or Puppy Mix with the identified distribution dates are advised by the agency to return the pet food mix where it was purchased or destroy the food so that children, pets and wildlife cannot get ahold of it, the statement reads.
Pet food bowls, cups, utensils and storage containers that might have come in contact with the product should also be washed.
Consumers who wish to learn more information can contact Blue Ridge Beef by emailing blueridgebeefnc@yahoo.com or calling 704-873-2072 Monday through Friday anytime from 8 a.m. to 5 p.m.
Westfield Fire Department trains at old rectory
Man arrested in Georgia brought back to Mass. to face domestic violence charges
Someone tried to firebomb a swing state governor's house. A suspect is hospitalized
Poll finds this person is the most popular political figure among dozens
Woburn District Court evacuated after incident involving pepper spray
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
an hour ago
- New York Times
F.D.A. Looks to A.I. to Enhance Efficiency
The Food and Drug Administration is planning to use artificial intelligence to 'radically increase efficiency' in deciding whether to approve new drugs and devices, one of several top priorities laid out in an article published Tuesday in JAMA. Another initiative involves a review of chemicals and other 'concerning ingredients' that appear in U.S. food but not in the food of other developed nations. And officials want to speed up the final stages of making a drug or medical device approval decision to mere weeks, citing the success of Operation Warp Speed during the Covid pandemic when workers raced to curb a spiraling death count. 'The F.D.A. will be focused on delivering faster cures and meaningful treatments for patients, especially those with neglected and rare diseases, healthier food for children and common-sense approaches to rebuild the public trust,' Dr. Marty Makary, the agency commissioner, and Dr. Vinay Prasad, who leads the division that oversees vaccines and gene therapy, wrote in the JAMA article. The agency plays a central role in pursuing the agenda of the U.S. health secretary, Robert F. Kennedy Jr., and it has already begun to press food makers to eliminate artificial food dyes. The new road map also underscores the Trump administration's efforts to smooth the way for major industries with an array of efforts aimed at getting products to pharmacies and store shelves quickly. Some aspects of the proposals outlined in JAMA were met with skepticism, particularly the idea that artificial intelligence is up to the task of shearing months or years from the painstaking work of examining applications that companies submit when seeking approval for a drug or high-risk medical device. 'I don't want to be dismissive of speeding reviews at the F.D.A.,' said Stephen Holland, a lawyer who formerly advised the House Committee on Energy and Commerce on health care. 'I think that there is great potential here, but I'm not seeing the beef yet.' Want all of The Times? Subscribe.
Bloomberg
an hour ago
- Bloomberg
FDA Pauses Trials of Gilead HIV Combination After Safety Signal
Gilead Sciences Inc. said federal regulators had placed on hold trials of a new experimental once-weekly HIV drug combination therapy after white blood cell counts dropped in some of the patients. The studies were testing two experimental HIV drugs, GS-1720 and GS-4182, when given together. Gilead said the Food and Drug Administration paused the trials due to a ' safety signal ' triggered by a decrease in lymphocyte levels in some patients given the therapy. Lymphocytes are a type of white blood cell that play a critical role in the immune system's ability to fight infections.
Medscape
an hour ago
- Medscape
Insmed's Drug for Rare Lung Disease Meets Main Goal in Mid-stage Trial
(Reuters) -Insmed said on Tuesday that its experimental drug significantly reduced blood pressure in the lungs and improved exercise capacity in patients in a mid-stage study, sending shares of the company up 26% in premarket trading. The drug, treprostinil palmitil, is a once-daily therapy that is inhaled through a device. The 102-patient study found that the drug helped reduce blood pressure in the patients' lungs by 35%, compared with a placebo. It also helped improve the patients' ability to walk by an average of 35.5 meters and reduced levels of a protein associated with heart stress by 60%. The company plans to discuss the trial data with the U.S. Food and Drug Administration and initiate a late-stage trial for the drug in patients with pulmonary arterial hypertension (PAH) — a rare disease caused by a constriction of arteries in the lungs, leading to high blood pressure - in early 2026. Insmed also plans to start a separate late-stage trial for the drug in patients with pulmonary hypertension associated with interstitial lung disease - a condition where lung scarring leads to high blood pressure in the lung arteries - before the end of 2025. Current treatment options available to treat PAH are Merck's injectable Winrevair and Liquidia's inhaled Yutrepia. (Reporting by Kamal Choudhury in Bengaluru; Editing by Maju Samuel) Reuters Health Information © 2025 Reuters Ltd.
